Porsolt expands laboratories and links up with Argenta
This article was originally published in Scrip
The French preclinical CRO Porsolt & Partners Pharmacology has started building a new 60,000ft2 laboratory facility near its site in Laval, France, which is expected to be completed early next year.
You may also be interested in...
The European Commission has extended the indications for Janssen’s Tremfya to include psoriatic arthritis, and those for BMS’s Opdivo to include gastroesophageal cancer.
Denmark’s biotech Genmab has dropped the AXL targeted antibody-drug conjugate, enapotamab vedotin from early clinical development, and is focusing its resources on other therapeutic programs.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.